References
- Clinical Synthesis Panel on HRT. Hormone replace-ment therapy. Lancet 1999;354:152–5
- Genazzani AR. Controversial issues in climacteric medicine. (I) Cardiovascular disease and hormone replacement therapy. International Menopause Society Expert Workshop, 13–16 October 2000, Royal Society of Medicine, London, UK. Maturitas 2001;38: 263–71
- Wassertheil-Smoller S, Anderson G, Psaty BM, et al. Hypertension and its treatment in postmenopausal women: baseline data from the Women's Health Initiative. Hypertension 2000;36:780–9
- Lip GYH, Beevers M, Churchill D, et al. Hormone replacement therapy and blood pressure in hyper-tensive women. J Hum Hypertens 1994;8:491–4
- Manhem K, Ahlm H, Milsom I, et al. Transdermal oestrogen reduces daytime blood pressure in hyper-tensive women. J Hum Hypertens 1998;2:323–7
- Mercuro G, Zoncu S, Piano D, et al. Estradio1-17beta reduces blood pressure and restores the normal amplitude of the circadian blood pressure rhythm in postmenopausal hypertension. Am J Hypertens 1998; 11:909–13
- Modena MG, Molinari R, Muia N Jr, et al. Double-blind randomized placebo-controlled study of transdermal estrogen replacement therapy on hypertensive postmenopausal women. Am J Hypertens 1999;12:1000–8
- Szekacs B, Vajo Z, Acs N, et al. Hormone replacement therapy reduces mean 24-hour blood pressure and its variability in postmenopausal women with treated hypertension. Menopause 2000;7:31–5
- De Lignieres B, Basdevant A, Thomas G, et al. Biological effects of estradiol-1713 in postmenopausal women: oral versus percutaneous administration. J Clin Endocrinol Metab 1986;62:536–41
- Kuttenn F, Gerson M, de Ligneres B. Effects of hormone replacement therapy in menopause on cardiovascular risk. Need for a European study. Presse Med 2002;31:468–75
- Lane G, Siddle NC, Ryder TA, et al. Dose dependent effects of oral progesterone on oestrogenised postmenopausal endometrium. Br Med J 1983;287: 1241–5
- Maxson WS, Hargrove JT. Bioavailability of oral micronized progesterone. Fertil Steril 1985;44:622–6
- Seely EW, Walsh BW, Gerhard MD, et al. Estradiol with or without progesterone and ambulatory blood pressure in postmenopausal women. Hypertension 1999;33:1190–4
- Spritzer PM, Vitola D, Vilodre LCF, et al. One-year follow-up of hormone replacement therapy with percutaneous estradiol and low-dose vaginal natural progesterone in women with mild to moderate hypertension. Exp Clin Endocrinol Diabetes 2003; in press
- Kupperman HS, Blatt, MH, Weisbader H, et al. Comparative clinical evaluation of estrogenic prepa-ration by the menopausal and amenorrhea indices. J Clin Endocrinol Metab 1953;6:688-703 study.
- Maturana MA, Spritzer PM. Association between hyperinsulinemia and endogenous androgen levels in pen and postmenopausal women. Metabolism 2002;51:238–43
- Vilodre LCF, Bertat R, Petters R, etal. Cervical polyp as risk factor for hysteroscopically diagnosed endo-metrial polyps. Gynecol Obstet Invest 1997;44:191–5
- Zar JH. Biostatistical Analysis, 3rd edn. Upper Saddle River: Prentice Hall, 1996:265–6
- The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. J Am Med Assoc 1995;273:199–208
- Devogelaer JP, Lecart C, Dupret P, et al. Long term effect of percutaneous estradiol on bone loss and bone metabolism in postmenopausal hysterectomized women. Maturitas 1998;28:243–9
- de Ziegler D, Ferriani R, Moraes LA, et al. Vaginal progesterone in menopause: Crinone 4% in cyclical andconstant combined regimens. Hum Rep rod2000;15(Suppl 1):149–58
- Archer DF, Pickar JH, Bottiglioni F. Bleeding patterns in postmenopausal women taking con-tinuous combined or sequential regimens of conju-gated estrogens with medroxyprogesterone acetate. Menopause Study Group. Obstet Gynecol 1994;83: 686–92
- Doren M, Reuther G, Minne HW, et al. Superior compliance and efficacy of continuous combined oral estrogen—progestogen replacement therapy in postmenopausal women. Am J Obstet Gynecol 1995; 173:1446–51